Coexistence of bronchiectasis and rheumatoid arthritis: Revisited

Respiratory Care

Volumn 58, Issue 4, 2013, Pages 694-701

  Wilczynska, Maria M ^a   Condliffe, Alison M ^b   McKeon, Damian J ^c  

^a PRINCE PHILIP HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c YSBYTY GWYNEDD   (United Kingdom)

Author keywords

Bronchiectasis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE;

BACTERIAL INFECTION; BRONCHIECTASIS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION TEST; LUNG INFECTION; MORTALITY; OBSTRUCTIVE AIRWAY DISEASE; PATHOGENESIS; PNEUMONIA; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; SMOKING CESSATION; TUBERCULOSIS;

RHEUMATOID ARTHRITIS, BRONCHIECTASIS;

ARTHRITIS, RHEUMATOID; BRONCHIECTASIS; HUMANS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84870889615     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.01857     Document Type: Review

References (75)

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36(3):182-188.
2. Roschmann RA, Rothenberg RJ. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum 1987;16(3):174-185.
3. Amital A, Shitrit D, Adir Y. The lung in rheumatoid arthritis. Presse Med 2011;40(1 Pt 2):e31-e48.
4. Aronoff A, Bywaters EG, Fearnley GR. Lung lesions in rheumatoid arthritis. Br Med J 1955;2(4933):228-232.
5. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12(4):205-209.
6. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007. Chest 2012;142(2):432-439.
7. Allain J, Saraux A, Guedes C, Valls I, Devauchelle V, Le Goff P. Prevalence of symptomatic bronchiectasis in patients with rheumatoid arthritis. Rev Rhum Engl Ed 1997;64(10):531-537.
8. Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A, et al; British Society for Rheumatology; British Health Professionals in Rheumatology. Guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 2009;48(4): 436-439.
9. Solanki T, Neville E. Bronchiectasis and rheumatoid disease: is there an association? Br J Rheumatol 1992;31(10):691-693.
10. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4 Pt 1): 1277-1284.
11. McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012;142(1):159-167.
12. Bamji A, Cooke N. Rheumatoid arthritis and chronic bronchial suppuration. Scand J Rheumatol 1985;14(1):15-21.
13. Shadick NA, Fanta CH, Weinblatt ME, O'Donnell W, Coblyn JS. Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine (Baltimore) 1994;73(3):161-170.
14. Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968;47(6):501-520.
15. Cortet B, Perez T, Roux N, Flipo RM, Duquesnoy B, Delcambre B, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997;56(10):596-600.
16. Metafratzi ZM, Georgiadis AN, Ioannidou CV, Alamanos Y, Vassiliou MP, Zikou AK, et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007;36(5):338-344.
17. Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012;64(6): 1756-1761.
18. McMahon MJ, Swinson DR, Shettar S, Wolstenholme R, Chattopadhyay C, Smith P, et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis 1993;52(11):776-779.
19. Snowden N, Moran A, Booth J, Haeney MR, Swinson DR. Defective antibody production in patients with rheumatoid arthritis and bronchiectasis. Clinical rheumatology 1999;18(2):132-135.
20. Casals T, De-Gracia J, Gallego M, Dorca J, Rodriguez-Sanchon B, Ramos MD, et al. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? Clin Genet 2004;65(6): 490-495.
21. Puechal X, Fajac I, Bienvenu T, Desmazes-Dufeu N, Hubert D, Kaplan JC, et al. Increased frequency of cystic fibrosis {increment}F508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999;13(6):1281-1287.
22. Puechal X, Bienvenu T, Genin E, Berthelot JM, Sibilia J, Gaudin P, et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis 2011; 70(4):653-659.
23. Hillarby MC, McMahon MJ, Grennan DM, Cooper RG, Clarkson RW, Davies EJ, et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 1993;32(9):794-797.
24. Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005; 25(6):429-435.
25. Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011;70(3):508-511.
26. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69(1):70-81.
27. Kaushik VV, Hutchinson D, Desmond J, Lynch MP, Dawson JK. Association between bronchiectasis and smoking in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63(8):1001-1002.
28. Remy-Jardin M, Remy J, Cortet B, Mauri F, Delcambre B. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994;193(2): 375-382.
29. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(5): 785-791.
30. Geri G, Dadoun S, Bui T, Del Castillo Pinol N, Paternotte S, Dougados M, et al. Risk of infections in bronchiectasis during diseasemodifying treatment and biologics for rheumatic diseases. BMC Infect Dis 2011;(11):304.
31. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998;157(5 Pt 1):1658-1665.
32. Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol 2011;21(2):164-173.
33. Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004;232(1):81-91.
34. Terasaki H, Fujimoto K, Hayabuchi N, Ogoh Y, Fukuda T, Muller NL. Respiratory symptoms in rheumatoid arthritis: relation between high resolution CT findings and functional impairment. Radiat Med 2004;22(3):179-185.
35. Goeminne PC, Verschueren P, Scheers H, Dupont LJ. Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis. Clin Rheumatol 2012;31(2):367-373.
36. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly C. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994;33(2):118-122.
37. Hassan WU, Keaney NP, Holland CD, Kelly CA. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 1995;54(4):308-310.
38. Hounsfield GN. Picture quality of computed tomography. AJR Am J Roentgenol 1976;127(1):3-9.
39. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-324.
40. Cortet B, Flipo RM, Remy-Jardin M, Coquerelle P, Duquesnoy B, Remy J, et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54(10):815-819.
41. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int 2012; 32(3):669-673.
42. Zrour SH, Touzi M, Bejia I, Golli M, Rouatbi N, Sakly N, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine 2005;72(1):41-47.
43. Mohd Noor N, Mohd Shahrir MS, Shahid MS, Abdul Manap R, Shahizon Azura AM, Azhar Shah S. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. Int J Rheum Dis 2009;12(2):136-144.
44. Demir R, Bodur H, Tokoglu F, Olcay I, Ucan H, Borman P. High resolution computed tomography of the lungs in patients with rheumatoid arthritis. Rheumatol Int 1999;19(1-2):19-22.
45. Izumiyama T, Hama H, Miura M. Frequency of broncho-bronchiolar disease in rheumatoid arthritis: an examination by high resolution computed tomography. Mod Rheumatol 2002;12(4):311-317.
46. Despaux J, Manzoni P, Toussirot E, Augé B, Cedoz JP, Wendling D. Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. Rev Rhum Engl Ed 1998;65(7-9):453-461.
47. Ong HK, Lee AL, Hill CJ, Holland AE, Denehy L. Effects of pulmonary rehabilitation in bronchiectasis: a retrospective study. Chron Respir Dis 2011;8(1):21-30.
48. Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997;36(6):689-691.
49. Scull E. Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis. Arthritis Rheum 1962;5:30-36.
50. Kersley GD, Palin AG. Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet 1959;2(7108):886-888.
51. Ellman P, Lawrence JS, Thorold GP. Gold therapy in rheumatoid arthritis. Br Med J 1940;2(4157):314-316.
52. Batterman RC, Hagemann PO. Treatment of rheumatoid arthritis: salicylates, corticosteroids. Postgrad Med 1959;25(1):96-101.
53. Williams GT. A comparative evaluation of newer corticosteroids in the treatment of rheumatoid arthritis. South Med J 1959;52(3):267-273.
54. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S179-S185.
55. Pinals RS. History of enteric coated sulfasalazine in rheumatoid arthritis. J Rheumatol Suppl 1988;16:1-4.
56. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000;47(2-3): 273-289.
57. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46(9):2294-2300.
58. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96(2):115-123.
59. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59(8):1074-1081.
60. Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007;34(11):2201-2203.
61. Boerbooms AMT, Kerstens PJSM, van Loenhout JWA, Mulder J, van de Putte LBA. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24(6):411-421.
62. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nakajima A, et al. The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/ week in patients with rheumatoid arthritis. Mod Rheumatol 2011; 21(4):444-448.
63. The Australian Multicentre Clinical Trial Group. Sulfasalazine in early rheumatoid arthritis. J Rheumatol 1992;19(11):1672-1677.
64. Chalmers IM, Sitar DS, Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 1990;17(6):764-770.
65. Rains CP, Noble S, Faulds D. Sulfasalazine A. Review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50(1):137-156.
66. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. Health Technol Assess 2011;15(14):1-278.
67. van Vollenhoven R, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010; 37(3):558-567. Erratum in: J Rheumatol 2010;37(10):2198.
68. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-1123.
69. Wiens A, Correr CJ, Venson R, Otuki MF, Pontarolo R. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 2010;30(8): 1063-1070.
70. Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol 2009;70(4):337-344.
71. Delabaye I, De Keyser F. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther 2010;12(3):R121.
72. Tugwell P, Singh JA, Wells GA. Biologicals for rheumatoid arthritis. BMJ 2011;343:d4027.
73. Geri G, Dadoun S, Paternotte S. The infectious risk of the lower respiratory tract is increased in patients with rheumatic diseases treated by biologic DMARDs, in particular in case of pre-existing colonisation. Arthritis Rheum 2010;62(Suppl):1648.
74. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(7):577.
75. McMahon MJ, Swinson DR. Younger onset of rheumatoid arthritis in patients with bronchiectasis. Br J Rheumatol 1993;32(Suppl):125.